(GDRX) Goodrx Holdings - Ratings and Ratios
Discount Card, Subscription, Telehealth
GDRX EPS (Earnings per Share)
GDRX Revenue
Description: GDRX Goodrx Holdings
GoodRx Holdings Inc (NASDAQ:GDRX) is a healthcare technology company listed on the NASDAQ exchange. As a common stock, it represents ownership in the company. The firms primary operations are in the United States, and it is classified under the Health Care Technology sub-industry according to the GICS (Global Industry Classification Standard).
The companys market capitalization stands at approximately $1.56 billion, indicating its size and investor recognition. With a forward Price-to-Earnings (P/E) ratio of 8.88, the market anticipates future earnings growth. The current Return on Equity (RoE) is 7.96%, suggesting that the company generates a reasonable return for its shareholders. The high P/E ratio of 57.83 may indicate that the stock is currently overvalued relative to its current earnings, or it reflects high growth expectations.
Key economic drivers for GDRX include the growing demand for healthcare technology solutions, the increasing adoption of telehealth services, and the expanding need for affordable healthcare pricing information. As a healthcare technology company, GDRXs performance is closely tied to these trends. Important KPIs to monitor would include revenue growth, customer acquisition costs, and the retention rate of its user base, as these metrics can indicate the companys ability to capitalize on the growing demand for its services.
To evaluate GDRXs investment potential, one must consider its competitive position within the healthcare technology sector, its ability to innovate and expand its service offerings, and its financial health, including cash flow generation and profitability. The companys beta of 1.243 suggests that its stock price is more volatile than the overall market, which could be a consideration for risk-averse investors.
GDRX Stock Overview
| Market Cap in USD | 1,494m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2020-09-23 |
GDRX Stock Ratings
| Growth Rating | -57.5% |
| Fundamental | 69.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -54.4% |
| Analyst Rating | 3.88 of 5 |
GDRX Dividends
Currently no dividends paidGDRX Growth Ratios
| Growth Correlation 3m | -69.5% |
| Growth Correlation 12m | -58% |
| Growth Correlation 5y | -78.7% |
| CAGR 5y | -9.13% |
| CAGR/Max DD 3y | -0.15 |
| CAGR/Mean DD 3y | -0.33 |
| Sharpe Ratio 12m | -0.80 |
| Alpha | 0.09 |
| Beta | 0.741 |
| Volatility | 64.02% |
| Current Volume | 2024.9k |
| Average Volume 20d | 2194.9k |
| Stop Loss | 3.9 (-4.9%) |
| Signal | -1.17 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (42.9m TTM) > 0 and > 6% of Revenue (6% = 48.0m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 7.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 52.47% (prev 83.61%; Δ -31.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 190.6m > Net Income 42.9m (YES >=105%, WARN >=100%) |
| Net Debt (266.2m) to EBITDA (178.1m) ratio: 1.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (357.2m) change vs 12m ago -7.17% (target <= -2.0% for YES) |
| Gross Margin 91.21% (prev 82.78%; Δ 8.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.25% (prev 52.53%; Δ 4.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.24 (EBITDA TTM 178.1m / Interest Expense TTM 45.1m) >= 6 (WARN >= 3) |
Altman Z'' -3.13
| (A) 0.32 = (Total Current Assets 550.6m - Total Current Liabilities 130.9m) / Total Assets 1.32b |
| (B) -1.07 = Retained Earnings (Balance) -1.42b / Total Assets 1.32b |
| warn (B) unusual magnitude: -1.07 — check mapping/units |
| (C) 0.07 = EBIT TTM 100.9m / Avg Total Assets 1.40b |
| (D) -2.10 = Book Value of Equity -1.42b / Total Liabilities 675.7m |
| Total Rating: -3.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.81
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 9.23% = 4.61 |
| 3. FCF Margin 19.70% = 4.92 |
| 4. Debt/Equity 0.77 = 2.21 |
| 5. Debt/Ebitda 2.78 = -1.43 |
| 6. ROIC - WACC (= -2.37)% = -2.96 |
| 7. RoE 6.31% = 0.53 |
| 8. Rev. Trend 83.96% = 6.30 |
| 9. EPS Trend 82.55% = 4.13 |
What is the price of GDRX shares?
Over the past week, the price has changed by -0.49%, over one month by -19.92%, over three months by -6.61% and over the past year by -45.98%.
Is Goodrx Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GDRX is around 3.32 USD . This means that GDRX is currently overvalued and has a potential downside of -19.02%.
Is GDRX a buy, sell or hold?
- Strong Buy: 7
- Buy: 1
- Hold: 7
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the GDRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.4 | 31% |
| Analysts Target Price | 5.4 | 31% |
| ValueRay Target Price | 3.7 | -11% |
Last update: 2025-09-04 04:38
GDRX Fundamental Data Overview
CCE Cash And Equivalents = 281.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 47.7778
P/E Forward = 11.7509
P/S = 1.8678
P/B = 2.3504
Beta = 1.243
Revenue TTM = 799.9m USD
EBIT TTM = 100.9m USD
EBITDA TTM = 178.1m USD
Long Term Debt = 485.0m USD (from longTermDebt, last quarter)
Short Term Debt = 9.82m USD (from shortTermDebt, last quarter)
Debt = 494.8m USD (Calculated: Short Term 9.82m + Long Term 485.0m)
Net Debt = 266.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.71b USD (1.49b + Debt 494.8m - CCE 281.3m)
Interest Coverage Ratio = 2.24 (Ebit TTM 100.9m / Interest Expense TTM 45.1m)
FCF Yield = 9.23% (FCF TTM 157.6m / Enterprise Value 1.71b)
FCF Margin = 19.70% (FCF TTM 157.6m / Revenue TTM 799.9m)
Net Margin = 5.36% (Net Income TTM 42.9m / Revenue TTM 799.9m)
Gross Margin = 91.21% ((Revenue TTM 799.9m - Cost of Revenue TTM 70.3m) / Revenue TTM)
Tobins Q-Ratio = -1.20 (set to none) (Enterprise Value 1.71b / Book Value Of Equity -1.42b)
Interest Expense / Debt = 2.17% (Interest Expense 10.7m / Debt 494.8m)
Taxrate = 47.90% (15.1m / 31.5m)
NOPAT = 52.5m (EBIT 100.9m * (1 - 47.90%))
Current Ratio = 4.21 (Total Current Assets 550.6m / Total Current Liabilities 130.9m)
Debt / Equity = 0.77 (Debt 494.8m / last Quarter total Stockholder Equity 643.0m)
Debt / EBITDA = 2.78 (Net Debt 266.2m / EBITDA 178.1m)
Debt / FCF = 3.14 (Debt 494.8m / FCF TTM 157.6m)
Total Stockholder Equity = 679.6m (last 4 quarters mean)
RoA = 3.25% (Net Income 42.9m, Total Assets 1.32b )
RoE = 6.31% (Net Income TTM 42.9m / Total Stockholder Equity 679.6m)
RoCE = 8.66% (Ebit 100.9m / (Equity 679.6m + L.T.Debt 485.0m))
RoIC = 4.49% (NOPAT 52.5m / Invested Capital 1.17b)
WACC = 6.85% (E(1.49b)/V(1.99b) * Re(8.75%)) + (D(494.8m)/V(1.99b) * Rd(2.17%) * (1-Tc(0.48)))
Shares Correlation 3-Years: -75.76 | Cagr: -1.31%
Discount Rate = 8.75% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.70% ; FCFE base≈120.2m ; Y1≈112.8m ; Y5≈105.4m
Fair Price DCF = 16.85 (DCF Value 1.66b / Shares Outstanding 98.6m; 5y FCF grow -7.87% → 3.0% )
EPS Correlation: 82.55 | EPS CAGR: 9.57% | SUE: -1.25 | # QB: 0
Revenue Correlation: 83.96 | Revenue CAGR: 2.98% | SUE: -0.78 | # QB: 0
Additional Sources for GDRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle